World

US vaccine advisers abandon broad COVID shot support

Sep 22, 2025

New York [US], September 22: A panel of vaccine advisers named by Health Secretary Robert F. Kennedy Jr. on Friday said that COVID-19 shots should be administered only through shared decision-making with a healthcare provider, scrapping a broad recommendation but maintaining access through health insurance.
The two-day meeting highlighted deep divisions over the future of the U.S. immunization schedules under Kennedy, who has long promoted claims about vaccine harms that run contrary to scientific evidence.
A second COVID vote by the committee, which advises the Centers for Disease Control and Prevention, would have recommended that states and local jurisdictions require a prescription for the COVID vaccine. That vote failed to win a majority.
The committee earlier on Friday abandoned a vote that would have delayed the first hepatitis B vaccine dose for newborns, giving a temporary win to doctors, public health experts and patient advocates who had decried the move.
On Thursday, the panel voted not to recommend giving the combined measles-mumps-rubella-varicella shot to children under 4 years old. But the advisers voted to allow coverage for the shot for these same kids under a U.S. government program that provides free vaccines to children, creating contradictory guidance.
On Friday morning, the committee reversed that vote to align the policy with their recommendation, removing coverage for the shots.
The acting director of the CDC will weigh in on whether to accept the recommendations.
Source: Fijian Broadcasting Corporation

More news

Infosys: Differentiated AI strategy and a sharp focus on value unlock propels 29% sequential growth in AI revenues

Bengaluru (Karnataka) [India], October 23: Infosys (NSE: INFY) (BSE: INFY) (NYSE: INFY), a global leader in AI-first business consulting and technology services, delivered $5,145 million in Q2 revenues, year on year growth of 1.5% and sequential growth of 1.2% in constant currency. Operating margin was stable at 21.0%. EPS growth was 8.7% year on year in rupee terms. TCV of large deal wins was $5.2 billion, with 62% net new. Robust Q2 large deal TCV at $5.2 billion with 62% net new; lays solid foundation for future growth. FY 27 revenue guidance revised to 1%-2% and margin guidance retained at 20%-22%.

Oct 23, 2026